Foghorn therapeutics provides third quarter 2022 financial and corporate update

- fhd-286 phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023
FHTX Ratings Summary
FHTX Quant Ranking